Or
Contact UsCisplatin has been around for decades, and that is exactly where the misunderstanding starts. Patients hear “old drug” and assume it is either outdated or mild. Neither is true. In oncology, a medicine stays in protocols because it still does something others cannot easily replace. Cisplatin is that kind of drug.
It goes into the vein, not into a pill bottle at home. And the infusion day is never just the infusion. Fluids before and after, anti-nausea medicines, urine monitoring, blood tests — all of this is planned around the drug, not added as an afterthought. Most patients say that part caught them off guard.
From day one, kidneys, hearing, nerves, blood, and mineral levels are all in the picture. Not because something bad is expected to happen, but because catching a change early is what keeps the plan on track.
Cancer cells need to copy themselves constantly. Cisplatin gets inside the cell and damages the DNA in a way that makes that copying unreliable or impossible. The cell tries to divide and cannot finish the job.
That mechanism sounds clean, but the body is not a controlled experiment. Some tumors are genuinely sensitive to platinum. Others respond less, or stop responding after earlier treatment. The same drug can drive a strong result in one patient and do very little in another — not because the drug changed, but because the biology did.
Getting Cisplatin into the body is only part of the equation. The real question is whether the full plan gives a real chance of benefit without pushing the patient into a level of toxicity that causes more harm than good.
Cisplatin appears in treatment plans across several cancer types, though the diagnosis alone does not decide anything.
Two patients with the same diagnosis can receive very different recommendations. One may get Cisplatin before surgery, another after. One may have it running with radiation, another in a metastatic setting where the goal is control rather than cure.
Oncologists tend to look at Cisplatin more seriously in certain situations where the expected benefit is clear and the patient is physically able to carry the treatment.
The useful question is not whether Cisplatin is used for a particular cancer type. It is what specific job it is supposed to do in this particular plan. Once that is clear, weighing the risks becomes a real conversation.
The oncologist needs more than a diagnosis before the first infusion. Details that seem minor to a patient can change a clinical decision.
Fertility needs its own conversation when it is relevant. Cisplatin can affect it, and the topic tends to get raised too late, when treatment pressure has already built up. Asking early is always better, even when the answer is not easy.
Cisplatin is given by intravenous infusion in a clinic or hospital. The schedule varies. Some protocols use a larger dose at wider intervals. Others use smaller weekly doses, particularly when the drug runs with radiation.
On infusion days the team manages fluids, nausea prevention, urine output and lab results. Anti-nausea medicines usually go in before the patient feels any discomfort, because Cisplatin can cause serious nausea when prevention is weak.
During and after treatment the team monitors:
A dose delay or reduction does not mean treatment has stopped working. Sometimes the body needs more recovery time. Sometimes a lab result says to wait. Understanding why the change happened matters more than reacting to it.
Nausea is the side effect patients mention first, and that fear is legitimate. Cisplatin can be genuinely hard on the stomach. But nausea is not the only concern, and some of the more serious problems show up in tests before the patient notices anything.
This is not a list meant to frighten. It is a list meant to help patients report early. A new sound in the ears, a change in how much urine is passing, or tingling that was not there last week — these are details that give the doctor a chance to act before a manageable issue becomes a reason to stop treatment.
Some symptoms during Cisplatin treatment should not wait for the next scheduled visit. Contact the medical team the same day if any of the following appear:
A patient does not need to prove the symptom is serious enough to call. With Cisplatin, early contact is often what keeps a problem from becoming a reason to interrupt or stop the plan.
Cisplatin has a real place in oncology, but a matching diagnosis does not make it automatically safe. The tumor may fit the drug while the patient’s body does not.
Major factors that can make Cisplatin unsafe or unsuitable:
This is also where the comparison with Carboplatin comes up. Carboplatin may be easier on the kidneys, ears and stomach, but it is not a milder copy that can substitute for Cisplatin in every situation. The right comparison requires knowing the diagnosis, treatment goal, kidney function, hearing status, previous therapy and how strong the expected benefit really is.
Yes, and it often is. Cisplatin can be paired with:
Combinations can increase effectiveness, but they also increase what the body has to carry. Cisplatin with radiation to the throat creates very different support needs from Cisplatin in a testicular cancer protocol. The drug name is identical. What the patient goes through may be completely different.
When reviewing a plan, the sequence matters. What has already been done? What is Cisplatin expected to add? What comes after? Which side effects might interfere with the next step? These questions are more useful than judging the drug on its own.
Cisplatin does not always give a clear answer fast. Some patients feel worse before any scan looks better. Some tumors reduce slowly. In situations where the drug is used after surgery or alongside radiation, there may be no single visible moment where everything is obviously working.
Treatment should not keep going on autopilot either. Cancer moving forward, toxicity crossing into unsafe territory, or a goal that no longer makes sense — any of these means the plan needs a real look. Cisplatin is one tool in the room. Not a promise.
Tel Aviv Medical Clinic offers oncology consultations and second opinions for patients considering or already on a Cisplatin-based plan. Useful when the protocol feels heavy, when kidney or hearing questions have not been properly addressed, when the family simply needs someone to explain the reasoning, or when alternatives have not been laid out clearly.
The consultation can cover:
We do not step in as the treating doctor. We help the patient walk into the next conversation prepared.
Age of a drug is not the right measure. Cisplatin stays in protocols because certain tumors still respond to it in ways that newer options have not consistently matched. What matters clinically is not when the drug was developed. It is whether it fits the tumor biology, the treatment goal and what the patient’s body can handle. When we look at a case, we go through all of that — not just the name on the bottle.
Carboplatin tends to sit easier on the kidneys, ears and stomach — but that is not the same as being better. Certain cancers hit back harder against Cisplatin, and some protocols were designed around that. When Carboplatin is the smarter call, it is usually because the body cannot safely carry what Cisplatin demands. None of this means anything without knowing the diagnosis, the stage, kidney numbers, what came before, and what the platinum is actually there to do.
Nausea gets most of the attention from patients, and understandably so. What we follow just as closely are the things that move quietly: kidney numbers, magnesium and potassium, blood counts, hearing, nerves. Changes here can show up in labs before the patient feels much of anything. Regular tests are not a formality — they are how we know whether the next infusion is safe to give.
When there is already tinnitus, existing hearing loss, noise-related damage or a history of ear problems, hearing should be looked at before treatment starts. Cisplatin can affect it, and the change is not always reversible. Not every patient needs the same level of assessment, but the conversation should happen early. It is much harder to manage properly after several cycles, when the patient mentions that a constant ringing appeared somewhere along the way.
Sometimes yes. The number on the birth certificate is not the answer. We look at kidney function, physical strength, nutrition, hearing, nerve health, other medical conditions and whether the treatment goal is realistic for that person. A fit older patient may go through a well-planned regimen without major problems, while a younger patient with kidney damage may not be a suitable candidate. Age is one line in the assessment, not the conclusion.
Pathology report, scans, any surgery notes, the list of previous treatments, the proposed chemo schedule, recent bloods. Kidney function and electrolytes matter most. Neuropathy, hearing shifts, bad nausea from earlier rounds — write those down with rough dates. One page with a clear timeline beats a folder of unsorted papers every time.
A delay does not mean the drug stopped working. Sometimes the kidneys need more time. Sometimes blood counts or electrolytes are not where they need to be for the next round. Pausing protects the patient and keeps the plan viable. The question worth asking is why it happened and whether recovery is going the right direction — not whether the delay itself is a bad sign.
This page gives general medical information. It is not a personal treatment plan. Cisplatin should be discussed only after review of the diagnosis, stage, kidney function, hearing, nerve symptoms, previous treatment and current blood tests.
Do not start, stop or change chemotherapy without your treating oncologist.
For consultation about Cisplatin treatment:
📞 +972-73-374-6844
📧 [email protected]
💬 WhatsApp: +972-52-337-3108
